-
Boehringer Ingelheim identifies SOS1 inhibitors for KRAS-mutant cancers
23 Oct 2025 22:43 GMT
-
Small Cell Lung Cancer Market Research 2025-2035, Competitive Analysis of Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Merck, Pfizer, PharmaMar, Sun Pharma, Teva - ResearchAndMarkets.com
23 Oct 2025 15:37 GMT
… care.
Companies Featured
Amgen
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
Genentech
Merck …
-
The Escalator: Novo Nordisk, Boehringer Ingelheim, Galapagos and more
23 Oct 2025 13:53 GMT
… as interim CEO.
Executive elevations:
Boehringer Ingelheim promoted Vani Manja to global …
-
Boehringer Ingelheim wins Korea approval for Metalyse to treat acute ischemic stroke
23 Oct 2025 07:31 GMT
Boehringer Ingelheim Korea said it received approval … of Specialty Care Franchise at Boehringer Ingelheim Korea. “Now that Metalyse has …
-
Boehringer Ingelheim's Jascayd approved in China to treat idiopathic pulmonary fibrosis
23 Oct 2025 07:15 GMT
Boehringer Ingelheim’s Jascayd (nerandomilast) has been … head of human pharma at Boehringer Ingelheim. “This milestone reflects our commitment … affects more men than women.
Boehringer Ingelheim is a biopharmaceutical company active …
-
Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
20 Oct 2025 12:13 GMT
… a range of cancers. Boehringer Ingelheim’s generational commitment to driving … cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, … today and for generations.
Boehringer Ingelheim is a biopharmaceutical company active …
-
Wegovy confers reductions in cardiovascular risk, regardless of weight loss
23 Oct 2025 20:23 GMT
… from Aegerion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Novo Nordisk, Pfizer …
-
Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica
23 Oct 2025 20:32 GMT
… the Radiopharmaceuticals Market
Bayer AG
Boehringer Ingelheim International GmbH
Bracco
Cardinal Health …
-
Regulatory actions for Oct. 23, 2025
23 Oct 2025 22:18 GMT
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Adarx, Amgen, Astellas, Astrazeneca, Boehringer Ingelheim, Electra.
BioWorld Briefs Regulatory actions
-
Sacituzumab govitecan improves outcomes for breast cancer subset
23 Oct 2025 20:23 GMT
… travel expenses, with AbbVie, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly …
About
© 1995-2025